PubMed COVID-19 Clinical Care

The COVID-19 pandemic disrupted livelihoods on different fronts and at varying degrees globally. The global education sector was one of the key sectors that bore the heaviest brunt, particularly in the teaching and learning delivery modes. For

The COVID-19 virus has unimaginably disrupted the transit system and its overall functions. Users' vigilant safety concerns posed by the pandemic and the consequent transit avoidance behaviour for a prolonged period could have lasting impacts on

This is a case of subcutaneous panniculitis-like T-cell lymphoma (SPTCL) was diagnosed by skin biopsy in a patient who presented with fever and erythema nodosum in the umbilicum following mRNA-1273 COVID-19 vaccination. COVID-19 vaccines may cause

No abstract

No abstract

This study aimed to examine the effects of COVID-19 risk perception on negative destination image and self-protection behavior, and the resultant effects on tourist satisfaction. Hence, this study applied a continuous interpretive mixed-method design

Since November 2021, there have been cases of COVID-19's Omicron strain spreading in competition with Delta strains in many parts of the world. To explore how these two strains developed in this competitive spread, a new compartmentalized model was

CONCLUSIONS: We developed a CAPA risk score as a noninvasive tool to aid in CAPA screening for patients with severe COVID-19. Our score will also identify a group of patients who are unlikely to have CAPA and who therefore need not undergo additional

CONCLUSIONS: IP-10 may predict progression to ARDS in patients with COVID-19 pneumonia and IL-6 levels >40 pg/mL. Importantly, IP-10 value <2500 pg/mL might discriminate those individuals who might not benefit from sarilumab therapy among those with high IL-6 levels.

Extension of the COVERALL (COrona VaccinE tRiAL pLatform) randomized trial showed noninferiority in antibody response of the third dose of Moderna mRNA-1273 vaccine (95.3% [95% confidence interval {CI}, 91.9%-98.7%]) compared to Pfizer-BioNTech